Obinutuzumab (G)

DRUG2 trials

Sponsors

Hoffmann-La Roche, InnoCare Pharma Inc.

Conditions

B-Cell LymphomaMature B-cell MalignanciesNon-Hodgkin Lymphoma

Phase 1

A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

CompletedNCT03467373

Hoffmann-La RocheB-Cell Lymphoma, Non-Hodgkin Lymphoma

Start: 2018-03-13End: 2024-12-02Updated: 2025-01-17

Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies

RecruitingNCT06351527

InnoCare Pharma Inc.Mature B-cell Malignancies

Start: 2024-04-23End: 2027-10-25Target: 78Updated: 2025-06-19

Related Papers

Efficacy and tolerability of mesutoclax monotherapy in Relapsed/Refractory Mantle Cell Lymphoma patients: High remission rates even in prior BTKi-refractory patients

Blood2025-11-03

Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma.

2025-10-012 citations

SKYGLO: A Global Phase III Randomized Study Evaluating Glofitamab Plus Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma (LBCL)

Blood2024-11-0513 citations

Glofitamab Plus R-CHOP Induces High Response Rates with a Manageable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A 12-Month Analysis from a Phase Ib Study

Blood2023-11-0224 citations

Glofitamab + Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from a phase Ib study.

Journal of Clinical Oncology2023-06-0120 citations

Glofitamab plus immunochemotherapy demonstrates durable efficacy with manageable safety in relapsed/refractory non‐Hodgkin lymphoma (R/R NHL): update of a Phase Ib study

Hematological Oncology2023-06-011 citations

Glofitamab Plus R-CHOP Induces High Response Rates and a Favorable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Phase Ib Study

Blood2022-11-1523 citations

Glofitamab Plus R-CHOP Induces High Response Rates with Minimal Cytokine Release Syndrome (CRS) in Patients (pts) with Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and Previously Untreated (1L) Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results from a Dose-Escalation and Safety Run-in Phase Ib Study

Blood2021-11-0512 citations